Abbott announced that the U.S. FDA has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring system sensors for integration with automated insulin delivery systems. Abbott modified the sensors to enable integration with AID systems. The modified sensors were also cleared for use by children as young as two years old and for wear time up to 15 days. Current FreeStyle Libre 2 and FreeStyle Libre 3 sensors available today in the U.S. are approved for people four years and older and have a wear time of up to 14 days.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABT:
- Abbott announces late-breaking data from landmark COAPT trial
- Abbott announces data from TRILUMINATE pivotal study
- CMS earlier Basal coverage approval adds confidence for DexCom, says BofA
- Abbott announces data for Navitor TAVI system
- Baird points to elements of Apple report making it ‘less worried’ about DexCom